Literature DB >> 11060579

Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy.

B J Maron1.   

Abstract

Sudden unexpected death, often occurring in young asymptomatic patients, is the most devastating facet of the natural history of hypertrophic cardiomyopathy (HCM). It appears to be the consequence of primary ventricular tachyarrhythmias arising in an electrically unstable myocardial substrate characterized by disorganized cellular architecture, ischemia, cell death, and replacement scarring. Although identification of the HCM patient subset at high risk for a catastrophic event with precision continues to present challenges, treatment strategies for the prevention of sudden death are now available. In particular, the implantable cardioverter-defibrillator has a high degree of efficacy in sensing and terminating potentially lethal ventricular tachyarrhythmias and a life-saving role in both the primary and secondary prevention of sudden cardiac death in HCM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060579     DOI: 10.1007/s11886-000-0037-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  35 in total

1.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

Review 2.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

3.  Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; T J Anan; W C Roberts
Journal:  Circulation       Date:  1981-04       Impact factor: 29.690

4.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings.

Authors:  M Mirowski; P R Reid; M M Mower; L Watkins; V L Gott; J F Schauble; A Langer; M S Heilman; S A Kolenik; R E Fischell; M L Weisfeldt
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245

5.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Authors:  B J Maron; I Olivotto; P Spirito; S A Casey; P Bellone; T E Gohman; K J Graham; D A Burton; F Cecchi
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

6.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

7.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients.

Authors:  H G Klues; A Schiffers; B J Maron
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

8.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study.

Authors:  B J Maron; D D Savage; J K Wolfson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-08       Impact factor: 2.778

9.  Hypertrophic cardiomyopathy: an important cause of sudden death.

Authors:  W J McKenna; J E Deanfield
Journal:  Arch Dis Child       Date:  1984-10       Impact factor: 3.791

10.  "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death.

Authors:  B J Maron; L C Lipson; W C Roberts; D D Savage; S E Epstein
Journal:  Am J Cardiol       Date:  1978-06       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.